Noa Biran, MD
Medical Oncology · Hackensack, NJNPI 1023277910
Payments from drug & device makers
Across 483 payments — averaging $11,923 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2.1M
- Janssen Research & Development, LLC$1.9M
- Karyopharm Therapeutics Inc.$1M
- Bristol Myers Squibb$150K
- Takeda Pharmaceuticals U.S.A., Inc.$128K
- Merck$119K
- plus $291K from 21 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 35 | $2,101,783 |
| Janssen Research & Development, LLC | 145 | $1,942,901 |
| Karyopharm Therapeutics Inc. | 35 | $1,026,568 |
| Bristol Myers Squibb | 29 | $150,135 |
| Takeda Pharmaceuticals U.S.A., Inc. | 27 | $128,044 |
| Merck | 4 | $118,955 |
| Pfizer | 27 | $60,028 |
| Johnson & Johnson | 74 | $58,705 |
| Sanofi | 25 | $49,787 |
| AbbVie | 12 | $36,219 |
| EMD Serono, Inc. | 1 | $19,492 |
| E.r. Squibb & Sons, L.L.C. | 14 | $19,261 |
| Janssen Scientific Affairs, LLC | 10 | $14,976 |
| Sanofi US Services Inc. | 3 | $12,219 |
| Legend Biotech USA Inc. | 4 | $5,303 |
| Janssen Global Services, LLC | 6 | $4,434 |
| Regeneron Healthcare Solutions, Inc. | 3 | $3,644 |
| GSK | 10 | $3,313 |
| Sanofi-aventis U.S. LLC | 2 | $2,011 |
| Menarini Silicon Biosystems, Inc. | 2 | $600 |
| Adaptive Biotechnologies Corporation | 3 | $299 |
| Pharmacyclics LLC, An Abbvie Company | 6 | $81 |
| Gilead | 2 | $59 |
| Secura Bio, Inc. | 1 | $23 |
| Ferring Pharmaceuticals Inc. | 1 | $20 |
| Tolmar, Inc. | 1 | $18 |
| Pharmaand GmbH | 1 | $18 |
How this compares
$5,758,897 in reported general payments places this provider in the 90th percentile of 112 medical oncology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Hackensack
- Martin GutierrezHackensack$41.8M
- James McCloskeyHackensack$17.1M
- Lori LeslieHackensack$11.9M
- Tatyana FeldmanHackensack$8.4M
- David SiegelHackensack$6.9M
- Andrew PecoraHackensack$4.5M
- Robert AlterHackensack$4.5M
- Jamie KoprivnikarHackensack$3.8M
- David VesoleHackensack$3M
- Deena GrahamHackensack$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.